In vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatis.
We evaluated the in vitro activity of GAR-936, a novel glycylcycline antibiotic, against ten isolates of Chlamydia pneumoniae and five strains of C. trachomatis. Susceptibility testing was done in HEp-2 cells. The MIC90s and MBC90s of GAR-936, doxycycline, ofloxacin and clarithromycin against C. pneumoniae were 0.125, 0.25, 0.25 and 0.06 mg/l, respectively. The MICs and MBCs of GAR-936, doxycycline, ofloxacin and clarithromycin against C. trachomatis were 0.03-0.125, 0.25, 0.25-0.5 and 0.06 mg/l, respectively. GAR-936 had excellent activity against both chlamydial species and may have a potential role in the treatment of human chlamydial infection.
Roblin
P M
PM
Department of Pediatrics, State University of New York, SUNY Health Science Center at Brooklyn, 11203-2098, USA.
Hammerschlag
M R
MR
D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002690:Chlamydia Infections / Q000382:microbiology; D002692:Chlamydia trachomatis / Q000187:drug effects*; D023521:Chlamydophila Infections / Q000382:microbiology; D016993:Chlamydophila pneumoniae / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology*; D018410:Pneumonia, Bacterial / Q000382:microbiology; D000078304:Tigecycline
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline